Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US0008991046
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG002NCK5M5
ADMA
ADMA Biologics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
ADMA Biologics Inc
ISIN
US0008991046
TICKER
ADMA
MIC
XNAS
REUTERS
ADMA.OQ
BLOOMBERG
ADMA US
Wed, 24.06.2026       ADMA Biologics
US0008991046

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ADMA Biologics between August 9, 2024 and March 25, 2026 and would like to discuss your legal rights, call Faruqi & Faruq...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Tue, 23.06.2026       ADMA Biologics
US0008991046

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 23, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Tue, 23.06.2026       ADMA Biologics
US0008991046

BENSALEM, Pa., June 23, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ADMA BIOLOGICS, INC. (ADMA), CONTACT...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Tue, 23.06.2026       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - June 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities c...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Tue, 23.06.2026       ADMA Biologics
US0008991046

NEW YORK, June 23, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA). Shareholders who purchased shares of ADMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Tue, 23.06.2026       ADMA Biologics
US0008991046

Philadelphia, Pennsylvania--(Newsfile Corp. - June 23, 2026) - Grabar Law Office is investigating whether certain officers and directors of ADMA Biologics, Inc. (NASDAQ: ADMA) breached their fiduciary duties to the company and its shareholders.What Is The Investigation About? Grabar Law Office is investigating allegations that ADMA's officers and...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Tue, 23.06.2026       ADMA Biologics
US0008991046

A securities fraud class action lawsuit has been filed on behalf of ADMA Biologics investors after its stock plummeted 29% due to Culper Research channel stuffing claims, potentially violating federal securities laws.NEW YORK, June 23, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action law...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Tue, 23.06.2026       ADMA Biologics
US0008991046

SAN DIEGO, June 23, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, inclusive (the "Class Period"), have until August 10, 2026 to seek appointment as lead plaintiff of the ADMA Biologics clas...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Tue, 23.06.2026       ADMA Biologics
US0008991046

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ADMA Biologics between August 9, 2024 and March 25, 2026 and would like to discuss your legal rights, call Faruqi & Faruq...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.06.2026       ADMA Biologics
US0008991046

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 22, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 22.06.2026       ADMA Biologics
US0008991046

Philadelphia, Pennsylvania--(Newsfile Corp. - June 22, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company") on behalf of investors who purchased or acquired ADMA common stock during the period from August 9, 2024 through March 25, 2026 (the "C...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.06.2026       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - June 22, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.06.2026       ADMA Biologics
US0008991046

LOS ANGELES, June 22, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Sun, 21.06.2026       ADMA Biologics
US0008991046

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”), have until August 10, 2026 to seek appointment as lead plaintiff of the ADMA Biologics class action lawsuit. Captione...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Sun, 21.06.2026       ADMA Biologics
US0008991046

NEW YORK, June 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 20...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Sun, 21.06.2026       ADMA Biologics
US0008991046

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ADMA Biologics between August 9, 2024 and March 25, 2026 and would like to discuss your legal rights, call Faruqi & Faruq...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Sat, 20.06.2026       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - June 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities c...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Sat, 20.06.2026       ADMA Biologics
US0008991046

NEW YORK and NEW ORLEANS, June 19, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NasdaqGM: ADMA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Fri, 19.06.2026       ADMA Biologics
US0008991046

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 19, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Fri, 19.06.2026       ADMA Biologics
US0008991046

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ADMA Biologics between August 9, 2024 and March 25, 2026 and would like to discuss your legal rights, call Faruqi & Faru...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 18.06.2026       ADMA Biologics
US0008991046

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 18, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.06.2026       ADMA Biologics
US0008991046

Did you buy ADMA securities between August 9, 2024 and March 25, 2026?Affected ADMA Investor SummaryWho: ADMA Biologics, Inc. (NASDAQ: ADMA)What: Securities fraud class action lawsuit filedClass Period: August 9, 2024 through March 25, 2026Deadline to Seek Lead Plaintiff Status: August 10, 2026Key Lawsuit Allegations: Material misstatements and/or...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.06.2026       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - June 18, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.06.2026       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - June 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities c...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.06.2026       ADMA Biologics
US0008991046

ADMA Biologics' SEC filings allegedly used boilerplate risk language and selective related party disclosures to obscure a channel stuffing scheme and undisclosed distributor operating from its own headquarters.NEW YORK, June 18, 2026 /PRNewswire/ -- SueWallSt examines the adequacy of ADMA Biologics, Inc.'s (NASDAQ: ADMA) risk disclosures and relat...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.06.2026       ADMA Biologics
US0008991046

NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are e...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.06.2026       ADMA Biologics
US0008991046

Philadelphia, Pennsylvania--(Newsfile Corp. - June 18, 2026) - Grabar Law Office is investigating whether certain officers and directors of ADMA Biologics, Inc. (NASDAQ: ADMA) breached their fiduciary duties to the company and its shareholders.What Is The Investigation About? Grabar Law Office is investigating allegations that ADMA's officers and...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.06.2026       ADMA Biologics
US0008991046

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ADMA Biologics between August 9, 2024 and March 25, 2026 and would like to discuss your legal rights, call Faruqi & Faruq...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Wed, 17.06.2026       ADMA Biologics
US0008991046

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 17, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Wed, 17.06.2026       ADMA Biologics
US0008991046

ADMA Biologics allegedly certified internal controls as effective while concealing channel stuffing and an undisclosed related party distributor operating from company headquarters.NEW YORK, June 17, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA) of a pending securities class action. Class Pe...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Wed, 17.06.2026       ADMA Biologics
US0008991046

SAN DIEGO, June 17, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), have until August 10, 2026 to seek appointment as lead plaintiff of the ADMA Bio...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Wed, 17.06.2026       ADMA Biologics
US0008991046

NEW YORK, June 16, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Tue, 16.06.2026       ADMA Biologics
US0008991046

Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. (ADMA Biologics) (NASDAQ: ADMA) on behalf of those who purchased or acquired ADMA Biologics securities between August 9, 2024 and M...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Tue, 16.06.2026       ADMA Biologics
US0008991046

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 16, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Tue, 16.06.2026       ADMA Biologics
US0008991046

Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming August 10, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026, inclusive (the “Clas...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Tue, 16.06.2026       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - June 16, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Tue, 16.06.2026       ADMA Biologics
US0008991046

NEW YORK, June 16, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA). Shareholders who purchased shares of ADMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Tue, 16.06.2026       ADMA Biologics
US0008991046

A securities fraud class action lawsuit has been filed on behalf of ADMA Biologics investors after its stock plummeted 29% due to Culper Research channel stuffing claims, potentially violating federal securities laws.NEW YORK, June 16, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action law...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Mon, 15.06.2026       ADMA Biologics
US0008991046

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 15, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Mon, 15.06.2026       ADMA Biologics
US0008991046

Law Offices of Howard G. Smith reminds investors of the upcoming August 10, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”).IF YOU ARE AN INVESTOR WHO...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Mon, 15.06.2026       ADMA Biologics
US0008991046

NEW YORK, June 15, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) and certain of its officers. This lawsuit seeks to recove...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Mon, 15.06.2026       ADMA Biologics
US0008991046

Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of ADMA Biologics, Inc. (NASDAQ: ADMA) failed to manage ADMA Biologics in an acceptable manner, breaching their fiduciary duties to ADMA Biologics, and whether ADMA Biologics and its shareholders have suffered damages as a result. Atto...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Mon, 15.06.2026       ADMA Biologics
US0008991046

San Diego, California--(Newsfile Corp. - June 15, 2026) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), have until August 10, 2026 to seek appointment a...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Sun, 14.06.2026       ADMA Biologics
US0008991046

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ADMA Biologics between August 9, 2024 and March 25, 2026 and would like to discuss your legal rights, call Faruqi & Faruq...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Sat, 13.06.2026       ADMA Biologics
US0008991046

NEW ORLEANS, June 12, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 10, 2026 to file lead plaintiff applications in a securities class action lawsuit against ADMA Biologics, Inc. (NasdaqGM: ADMA) ("ADMA" or the "Company"), if they purchased or otherwise acquired the Company'...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Sat, 13.06.2026       ADMA Biologics
US0008991046

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”), have until August 10, 2026 to seek appointment as lead plaintiff of the ADMA Biologics class action lawsuit. Captione...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Sat, 13.06.2026       ADMA Biologics
US0008991046

SAN DIEGO, June 12, 2026 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9,2024 and March 25, 2026. ADMA Biologics, Inc., is a biopharmaceutical company, develops, manufactures, and markets spe...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.06.2026       ADMA Biologics
US0008991046

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 12, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.06.2026       ADMA Biologics
US0008991046

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026, inclusive (the “C...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.06.2026       ADMA Biologics
US0008991046

New York, New York--(Newsfile Corp. - June 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"). A class action lawsuit ha...
Read more
ADMA Biologics
Technical Analysis Termsheets Terminal
Permalink